Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
CTIM-76 Phase 1 trial focused on CLDN6-positive gynecologic and testicular cancers Trial marks key milestone in driving ...
manilatimes13d
Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors
PHILADELPHIA, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context” or the "Company”) (Nasdaq: CNTX), a ...
Yahoo Finance13d
Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors
PHILADELPHIA, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid ...
Context Therapeutics Inc. (NASDAQ:CNTX) Given Consensus Rating of “Buy” by Analysts
Shares of Context Therapeutics Inc. (NASDAQ:CNTX – Get Free Report) have earned a consensus rating of “Buy” from the seven brokerages that are covering the stock, MarketBeat.com reports. Six research ...
Context Therapeutics appoints PAsternak as Chairman of board of directors
Context Therapeutics (CNTX) announced the appointment of Andy Pasternak as Chairman of its Board of Directors, succeeding Richard Berman, who ...
Context Therapeutics Inc.: Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
CTIM-76 Phase 1 trial focused on CLDN6-positive gynecologic and testicular cancers Trial marks key milestone in driving pipeline progress PHILADELPHIA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Context Therap ...
Nasdaq13d
Context Therapeutics Inc. Appoints Andy Pasternak as Chairman of the Board to Drive Company's Growth in T Cell Engager Development
This leadership change signifies a transformation of the Board, positioning Context Therapeutics for future growth in the competitive biopharmaceutical market. Pasternak's extensive background ...
Morningstar11d
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
PHILADELPHIA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid ...
Business Insider13d
Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors
Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced the appointment of Andy ...
Nasdaq11d
Context Therapeutics Doses First Patient in Phase 1 Trial of CTIM-76 for CLDN6-Positive Cancers
Context Therapeutics announces first patient dosed in Phase 1 trial of CTIM-76 for CLDN6-positive cancers. Initial data expected 2026. Context Therapeutics Inc. has announced the dosing of the ...